Tonix Pharmaceuticals Holding Corp. strikes deal with Katana Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. strikes deal with Katana Pharmaceuticals for expanding the use of its intranasal drug to treat metabolic disorders like obesity, insulin resistance, and diabetes. Earlier, Tonix Pharma had acquired an exclusive license to the University of Geneva’s technology. This license would allow, Tonix to use Oxytocin for the treatment of insulin resistance and other related syndromes. It allows Tonix to expand the TNX-1900, into cardio metabolic syndromes, potentiated Oxytocin Development Program. The patent for this technology will provide Tonix liberty to operate in these indications and on its approval, will also give market exclusivity in the U.S. and Europe.

In June 2020, Tonix Pharmaceutical purchased its original potentiated oxytocin technology and development program from Trigemina, Inc. Tonix acquired its licenses for certain related technologies from Stanford University. The license is an addition to the company’s original purchase of oxytocin-potentiated therapy from Trigemina, which showed efficiency in preclinical data of oxytocin product TNX 1900 used to treat the disorders of the central nervous system including migraine.

Key opinion leaders (KOLs) are likely to welcome the administration of therapies through oral or related methods. On being interviewed by the GlobalData they have expressed concern over the continuous challenge in compliance by the Type 2 diabetic patients. According to reports, TNX 1900 can prove beneficial to increase the compliance thus obtaining a significant market share as compared to the traditional f=drug classes that adhere to subcutaneously administered biological therapies.

“Subsequent to the University of Geneva inventions, a number of studies have shown that intranasal oxytocin has effects on insulin resistance and weight,” said Dr Lederman. Intranasal oxytocin has shown positive effects like improvement in pancreatic β-cell responsivity, increase in glucose homeostasis, decrease in energy-induced and reward-induced eating, and has supported conscious control of food choices.

For more latest news Click Here

Follow Us
Twitter: @TimesTechPharm1

Leave a Reply

Your email address will not be published. Required fields are marked *